National Bank of Canada FI Buys 275,715 Shares of Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on Apr 7th, 2023

National Bank of Canada FI lifted its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 26.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,317,234 shares of the company’s stock after acquiring an additional 275,715 shares during the period. National Bank of Canada FI owned 0.05% of Johnson & Johnson worth $232,660,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Glassy Mountain Advisors Inc. acquired a new stake in Johnson & Johnson in the 4th quarter valued at approximately $35,000. Retirement Financial Solutions LLC acquired a new stake in Johnson & Johnson in the 4th quarter valued at approximately $40,000. TD Capital Management LLC acquired a new stake in Johnson & Johnson in the 3rd quarter valued at approximately $48,000. Iron Horse Wealth Management LLC grew its holdings in Johnson & Johnson by 112.8% in the 4th quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock valued at $53,000 after buying an additional 159 shares during the last quarter. Finally, Piershale Financial Group Inc. acquired a new stake in Johnson & Johnson in the 4th quarter valued at approximately $61,000. 67.94% of the stock is owned by institutional investors.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $165.15 on Friday. The stock’s fifty day simple moving average is $157.44 and its 200 day simple moving average is $167.03. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.99 and a quick ratio of 0.77. The firm has a market cap of $430.10 billion, a price-to-earnings ratio of 24.50, a P/E/G ratio of 2.70 and a beta of 0.53. Johnson & Johnson has a one year low of $150.11 and a one year high of $186.69.

Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 EPS for the quarter, beating the consensus estimate of $2.22 by $0.13. The business had revenue of $23.71 billion for the quarter, compared to analyst estimates of $23.90 billion. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. Johnson & Johnson’s quarterly revenue was down 4.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.13 EPS. On average, analysts expect that Johnson & Johnson will post 10.5 earnings per share for the current fiscal year.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of Johnson & Johnson stock in a transaction on Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the completion of the transaction, the insider now owns 9,215 shares in the company, valued at approximately $1,425,191.90. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Citigroup raised their target price on Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a report on Monday, December 12th. Guggenheim assumed coverage on Johnson & Johnson in a report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price objective on the stock. SVB Leerink decreased their price objective on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a report on Friday, January 20th. Atlantic Securities lifted their price objective on Johnson & Johnson from $160.00 to $168.00 and gave the stock a “neutral” rating in a report on Wednesday, January 25th. Finally, Morgan Stanley lifted their price objective on Johnson & Johnson from $176.00 to $180.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 25th. Eight research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $173.67.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.